Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair

16 Apr 2013

Abstract excerpt

High resistance to traditional chemo- and radiotherapies contributes to the poor prognosis of pancreatic cancer (PC). Methyl-CpG binding domain protein 1 (MBD1), which plays an important role in disease progression, contributes to the drug resistance of PC cells; however, the mechanism underlying the drug resistance endowed by MBD1 remains unknown. In this study, we found that MBD1 was recruited to DNA damage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to Drug Transport and Resistance Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23588667
DOI: 10.3892/ijo.2013.1901

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repairPMID 23588667Read ↗

DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparibSemantic proximity Read ↗

Roles for MDC1 in cancer development and treatment.Semantic proximity Read ↗

DNMT1 as a therapeutic target in pancreatic cancer: mechanisms and clinical implicationsSemantic proximity Read ↗

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtypeSemantic proximity Read ↗

CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic CancerSemantic proximity Read ↗

A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancerSemantic proximity Read ↗

Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to γ-irradiation.Semantic proximity Read ↗

Elevated PAF1-RAD52 axis confers chemoresistance to human cancersSemantic proximity Read ↗

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors.Semantic proximity Read ↗

Genome‑wide DNA hypomethylation drives a more invasive pancreatic cancer phenotype and has predictive occult distant metastasis and prognosis potential.Semantic proximity Read ↗

Inhibition of Non-Homologous End Joining Repair Impairs Pancreatic Cancer Growth and Enhances Radiation ResponseSemantic proximity Read ↗

Defective homologous recombination and genomic instability predict increased responsiveness to carbon ion radiotherapy in pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.